Earnings and Investment

$8 billion division grew 4.1% for the quarter

Trump's tariff announcements led to a stock market meltdown with trillions of dollars of losses from retirement accounts — at least on paper. What now? Here's what investors should consider.

The company also expects to submit its application for 510(k) clearance for its OneRF Trigeminal Nerve Ablation System in May, sooner than expected.

Swiss-based company’s plant will increase capacity to meet demand for autoinjectors

Under the terms, Boston Scientific will pay about $443 million upfront, plus up to $221 million if regulatory milestones occur.

Investment will support the expansion of its FDA-approved therapy designed to improve upper extremity function in chronic ischemic stroke survivors.